UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (date of earliest event reported): **November 19, 2019**

Heat Biologics, Inc.

(Exact name of registrant as specified in charter)

Delaware
(State or other jurisdiction of incorporation)

001-35994	**26-2844103**
(Commission File Number)	*(IRS Employer Identification No.)*

627 Davis Drive
Morrisville, North Carolina 27560
(Address of principal executive offices and zip code)

(919) 240-7133
(Registrant's telephone number including area code)

N/A
(Former Name and Former Address)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of registrant under any of the following provisions:

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12(b) under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class	Trading Symbol(s)	Name of each exchange on which registered
Common Stock, $0.0002 par value per share	HTBX	The Nasdaq Capital Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by checkmark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 7.01 Regulation FD Disclosure.

Members of the management team of Heat Biologics, Inc. (the "Company") and certain clinical investigators in itsongoing Phase 2 study investigating HS-110 in combination with Bristol-Myers Squibb's anti-PD-1 checkpoint inhibitor, nivolumab (Opdivo®) presented the information in the presentation poster (the "Poster") entitled "Viagenpumatucel-L (HS-110) plus nivolumab in previously-treated patients with advanced non-small cell lung cancer (NSCLC)" on November 19, 2019 at the American Association for Cancer Research (AACR) Special Conference on Tumor Immunology and Immunotherapy held in Boston Massachusetts. A copy of the Poster is attached to this Current Report on Form 8-K as Exhibit 99.1 and is incorporated herein by reference.

The furnishing of the attached Poster is not an admission as to the materiality of any information therein. The information contained in the Poster is summary information that is intended to be considered in the context of more complete information included in the Company's filings with the Securities and Exchange Commission (the "SEC") and other public announcements that the Company has made and may make from time to time by press release or otherwise. The Company undertakes no duty or obligation to update or revise the information contained in this report or the exhibit, although it may do so from time to time as its management believes is appropriate. Any such updating may be made through the filing of other reports or documents with the SEC, through press releases or through other public disclosures.

Item 8.01 Other Events.

On November 19, 2019, members of the management team of the Company and certain clinical investigators in itsongoing Phase 2 study investigating HS-110 in combination with Bristol-Myers Squibb's anti-PD-1 checkpoint inhibitor, nivolumab (Opdivo®) presented the Poster at the American Association for Cancer Research (AACR) Special Conference on Tumor Immunology and Immunotherapy held in Boston, Massachusetts. The Poster provides additional top line data from the Company's ongoing Phase 2 study investigating HS-110 in combination with Bristol-Myers Squibb's anti-PD-1 checkpoint inhibitor, nivolumab (Opdivo®). The additional data were obtained from Cohort A patients.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits.

The following exhibit is filed with this Current Report on Form 8-K:

Exhibit Number	Description
99.1	Poster presentation entitled "Viagenpumatucel-L (HS-110)) plus nivolumab in previously-treated patients with advanced non-small cell lung cancer (NSCLC)

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Dated: November 19, 2019

HEAT BIOLOGICS, INC.

By: /s/ Jeffrey Wolf
Name: Jeffrey Wolf
Title: Chairman, President and Chief Executive Officer

EXHIBIT INDEX

Exhibit Number	Description
99.1	Poster presentation entitled “Viagenpumatucel-L (HS-110)) plus nivolumab in previously-treated patients with advanced non-small cell lung cancer (NSCLC)

EXHIBIT 99.1


VIAGENPUMATUCEL-L (HS-110) IN COMBINATION WITH NIVOLUMAB IN PREVIOUSLY-TREATED PATIENTS WITH ADVANCED NON-SMALL LUNG CANCER (NSCLC)
Daniel Morgensztern[1], Lyudmila Bazhenova[2], Saiama N. Waqar[1], Lori McDermott[3], Jeff Hutchins[3], Wael Harb[4], Nathan Pennell[5], Roger B. Cohen[6]
Background
Patient Characteristics
Overall Survival
Median OS: 16.3 months
Progression Free Survival
Median PFS: 1.8 months
Frequently Reported Adverse Events
Mechanism of Action
Best Overall Response
T Cell Changes by Best Overall Response (BOR)
Study Schema
Best Target Lesion Response
Duration of Clinical Benefit
Conclusions
References
Acknowledgements